The Federal Circuit affirmed the district court's judgment following a bench trial that Sandoz Inc. infringed U.S. Patent No. 9,867,919, assigned to Duke University and licensed to Allergan Sales, LLC, which claims bimatoprost formulations for treating glaucoma and ocular hypertension. The court held that Sandoz's proposed generic product literally infringed the asserted claims and that those claims were not invalid for obviousness. The central legal questions concerned claim construction of concentration ranges and particle size limitations, and whether substantial evidence supported the district court's factual findings on infringement and obviousness. The court applied the clear error standard to the district court's findings that Sandoz's formulation fell within the claimed parameters, resolving a dispute between competing expert testimony regarding particle size measurements where Sandoz's expert testified to a mean of 4,230 nanometers and Allergan's expert testified to 1,620 nanometers.
The decision reinforces deference to district court credibility determinations in bench trials involving conflicting expert testimony on pharmaceutical formulation parameters, particularly where measurement methodologies differ. The affirmance signals that generics seeking to design around patented concentration and particle size ranges face a demanding burden when district courts credit patentee expert evidence on formulation characteristics, even where the parties' experts reach substantially different quantitative conclusions using different analytical techniques. The opinion provides practitioners with guidance on presenting and challenging expert testimony regarding bimatoprost formulations specifically, and more broadly illustrates how Federal Circuit review of bench trial findings operates in Hatch-Waxman cases where physical and chemical properties must be proven through dueling expert methodologies rather than direct documentary evidence.